Medicare AdvantageAdministrativeLow impact
MA07.047h, Pain Management of Peripheral Nerves by Injection
Independence Blue Cross·NJ · Pain Management, Orthopedics, Podiatry +1 more·Pharmacy
We identified it
Jun 19, 2026
Summary
This is a reissue with no substantive changes to Independence Blue Cross Medicare Advantage policy MA07.047h. The policy was rereviewed on 11/26/2025 per annual review process and remains unchanged. Billing teams should confirm their current processes align with the existing coverage criteria for peripheral nerve injections (carpal tunnel, tarsal tunnel, and intermetatarsal neuromas), the three-injection limit per site in six months, and the two-site maximum per session rule.
Action Required
No immediate action required. This is a reissue with no changes. Verify that current billing processes remain compliant with existing policy requirements: (1) Peripheral nerve injections are covered only for carpal tunnel syndrome, tarsal tunnel syndrome, and intermetatarsal/interdigital neuromas when medical necessity criteria are met; (2) Claims for more than three injections per anatomic site in a six-month period will be denied; (3) Claims for more than two anatomic sites injected in a single session will be denied. If your practice has not yet implemented controls to enforce these limits, add validation rules to your billing system to flag or reject claims exceeding these thresholds before submission to Independence Blue Cross.